Areas of Focus
Personalized medicine is evolving. Policy must evolve with it.
PHA works across areas of healthcare where patient access, independent clinical judgment, evidence, and regulation intersect.
Our areas of work may evolve as medicine changes, but our guiding principle remains constant: protect the Patient-Provider Partnership and help healthcare policy keep pace with modern care.
Areas of Focus
Where PHA Engages
Telemedicine & Patient Access
Advancing durable policy that supports responsible virtual care, continuity for patients, and clear rules for providers.
State Patient-Provider Protection
Engaging when state legislation, medical-board guidance, pharmacy-board policy, or other regulatory action may affect individualized care and independent clinical judgment.
Compounding
Supporting appropriate quality and safety standards while preserving lawful access to patient-specific compounded therapies.
Regenerative Medicine
Advancing clear, responsible pathways for provider-directed regenerative care and patient access.
Peptides & Emerging Therapies
Addressing policy and regulatory issues that affect access to novel and individualized treatments as science and clinical practice evolve.
Hormonal & Metabolic Health
Supporting modern, evidence-based standards for individualized hormonal and metabolic care.
Clinical Research & Evidence
Exploring modern approaches to physician-led research, real-world evidence, registries, and other methods of generating evidence in personalized medicine.
Areas of Focus
How These Areas Fit Together
PHA is not defined by a fixed list of therapies or policy issues.
Across every area of work, we apply the same principles: protect patients, preserve responsible access, support independent clinical judgment, strengthen evidence, and advance policy that can evolve alongside medicine.
This allows PHA to respond to emerging healthcare issues while keeping the Patient-Provider Partnership at the center of our work.
Get Involved
Have an issue that belongs at the table?
PHA works with providers, researchers, healthcare organizations, and other stakeholders facing policy or regulatory challenges in personalized healthcare.
Contact PHA